Dnajb1-KO Mouse
一般名
Dnajb1-KO
製品ID
S-KO-16489
背景情報
C57BL/6JCya
系統ID
KOCMP-81489-Dnajb1-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Dnajb1-KO Mouse（カタログ番号S-KO-16489）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Dnajb1-KO
系統ID
KOCMP-81489-Dnajb1-B6J-VB
遺伝子名
製品ID
S-KO-16489
遺伝子別名
DjB1, Hdj1, HSPF1, Hsp40, 0610007I11Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 8
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000005620
NCBIトランスクリプトID
NM_018808.3
ターゲット領域
Exon 2~3
有効領域の大きさ
~2.8 kb
遺伝子研究の概要
Dnajb1, also known as DnaJ homolog subfamily B member 1, is involved in multiple cellular processes. It negatively regulates MIG6 to promote epidermal growth factor receptor signaling by enhancing K48-linked ubiquitination of MIG6 [6]. It also destabilizes PDCD5 through ubiquitin-mediated degradation, suppressing p53-mediated apoptosis [7].
The DNAJB1-PRKACA fusion is a significant finding related to Dnajb1. This fusion is the oncogenic driver in fibrolamellar hepatocellular carcinoma (FLC). Peptide-based immunotherapy targeting DNAJB1-PRKACA can induce multifunctional cytotoxic CD8+ and T-helper 1 CD4+ T cells, and vaccination with its-derived peptides can lead to durable relapse-free survival in FLC patients [1]. Endogenous CD8 T cell responses to this fusion in FLC patients are rare, but functional fusion-specific T cell receptors (TCRs) have been defined, which could be used in cellular immunotherapies [2]. The DNAJB1-PRKACA fusion drives FLC through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming [3]. It also regulates LINC00473, which promotes tumor growth and alters mitochondrial fitness in FLC [4,5]. Additionally, DNAJB1-PRKACA fusions are not specific to FLC as they also occur in oncocytic pancreatic and biliary neoplasms, and protein kinase inhibition could be a potential therapy for these neoplasms [8].
In conclusion, Dnajb1 plays important roles in regulating key cellular signaling pathways and apoptosis. The discovery of the DNAJB1-PRKACA fusion has illuminated its significance in FLC and other related neoplasms. Studies on this fusion, especially in the context of FLC, have provided insights into potential immunotherapeutic and targeted treatment strategies for these diseases.
References:
1. Bauer, Jens, Köhler, Natalie, Maringer, Yacine, Hailfinger, Stephan, Walz, Juliane S. 2022. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. In Nature communications, 13, 6401. doi:10.1038/s41467-022-33746-3. https://pubmed.ncbi.nlm.nih.gov/36302754/
2. Kirk, Allison M, Crawford, Jeremy Chase, Chou, Ching-Heng, Strome, Scott E, Thomas, Paul G. . DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. In Cell reports. Medicine, 5, 101469. doi:10.1016/j.xcrm.2024.101469. https://pubmed.ncbi.nlm.nih.gov/38508137/
3. Gritti, Ilaria, Wan, Jinkai, Weeresekara, Vajira, Gujral, Taranjit S, Bardeesy, Nabeel. . DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming. In Cancer discovery, 15, 382-400. doi:10.1158/2159-8290.CD-24-0634. https://pubmed.ncbi.nlm.nih.gov/39326063/
4. Ma, Rosanna K, Tsai, Pei-Yin, Farghli, Alaa R, Barrow, Joeva, Sethupathy, Praveen. 2024. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma. In PLoS genetics, 20, e1011216. doi:10.1371/journal.pgen.1011216. https://pubmed.ncbi.nlm.nih.gov/38512964/
5. Kim, Stephanie S, Kycia, Ina, Karski, Michael, Sethupathy, Praveen, Vakili, Khashayar. 2022. DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling. In PloS one, 17, e0263829. doi:10.1371/journal.pone.0263829. https://pubmed.ncbi.nlm.nih.gov/35167623/
6. Park, Soo-Yeon, Choi, Hyo-Kyoung, Seo, Jae Sung, Choi, Kyung-Chul, Yoon, Ho-Geun. 2015. DNAJB1 negatively regulates MIG6 to promote epidermal growth factor receptor signaling. In Biochimica et biophysica acta, 1853, 2722-30. doi:10.1016/j.bbamcr.2015.07.024. https://pubmed.ncbi.nlm.nih.gov/26239118/
7. Cui, Xiandan, Choi, Hyo-Kyoung, Choi, Young-Seok, Choi, Kyung-Chul, Yoon, Ho-Geun. 2014. DNAJB1 destabilizes PDCD5 to suppress p53-mediated apoptosis. In Cancer letters, 357, 307-315. doi:10.1016/j.canlet.2014.11.041. https://pubmed.ncbi.nlm.nih.gov/25444898/
8. Vyas, Monika, Hechtman, Jaclyn F, Zhang, Yanming, Klimstra, David S, Basturk, Olca. 2019. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. In Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 33, 648-656. doi:10.1038/s41379-019-0398-2. https://pubmed.ncbi.nlm.nih.gov/31676785/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。